Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$0.00 – $0.02
1% from low
Exchange
OTC Link
OS
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $204.9K | $364.6K | $133.5K | $1.3M | $1.0M | $960.5K | $888.8K | $1.1M |
| Cost of revenue | $75.7K | $226.1K | $204.7K | $170.7K | $1.1K | $1.2M | $93.1K | $34.5K |
| Gross profit | $129.2K | $138.5K | −$71.2K | $1.1M | $1.0M | −$1.2M | −$93.1K | $1.1M |
| Gross margin | 63.1% | 38.0% | -53.3% | 86.5% | 99.9% | -120.2% | -10.5% | 100.0% |
| R&D | $3.3M | $394.9K | $360.0K | $430.8K | $802.9K | $307.1K | $14.3K | $26.4K |
| Operating income | −$16.3M | −$6.6M | −$3.8M | $27.2K | −$504.2K | $18.1K | −$2.1M | $128.3K |
| EBITDA | −$15.0M | −$6.6M | −$3.7M | −$1.3M | −$2.6M | −$2.5M | −$1.3M | −$857.1K |
| Net income | −$16.3M | −$6.6M | −$3.9M | −$1.5M | −$12.7M | −$3.1M | −$1.2M | −$943.2K |
| Net margin | -7956.1% | -1806.5% | -2900.7% | -117.7% | -1264.7% | -319.7% | -139.2% | -83.5% |
| EPS (diluted) | -0.08 | -0.59 | -0.09 | -0.02 | -0.12 | -0.02 | -0.00 | -0.00 |
Annual figures · source: Financial Modeling Prep
TRIVARX LTD
No one on the platform currently holds MDBIF.
No tracked institution reports a position in MDBIF as of their last filing.
| Execution date | Ratio |
|---|---|
| 2023-10-24 | 1-for-20reverse |
No one on the platform has traded MDBIF yet.
| +0.00% |
| $7M |
| — |
| OXBOFOxford BioDynamics Plc | $0.00 | +0.00% | $6M | — |
| PAXHPreAxia Health Care Payment Systems Inc. | $0.22 | +0.00% | $4M | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Trading at 3.8× sales vs its 4.1× historical median P/S.
Fair value ≈ $0.00 · price $0.00 today
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.